Paediatric Respiratory Tract Infections: Present Considerations—Future Prospectives

A special issue of Diseases (ISSN 2079-9721).

Deadline for manuscript submissions: closed (30 June 2020) | Viewed by 3304

Special Issue Editors


E-Mail Website
Guest Editor
3rd Department of Pediatrics, Hippokration General Hospital, Aristotle University of Thessaloniki, 546 42 Thessaloniki, Greece
Interests: pediatric infectious diseases; epidemiology; healthcare-associated infections
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
Paediatric Department, 424 General Military Hospital, Thessaloniki, Greece
Interests: pediatric respiratory medicine; paediatrics

Special Issue Information

Dear Colleagues,

Infectious diseases of the respiratory tract are the most common disease entity in Pediatrics worldwide, with millions of children affected every year. Even though existing scientific knowledge in this field is well established and thorough, various factors such as the re-emergence of vaccine-preventable diseases, the refugee crisis, along with increasing antibiotic resistance, shortage of pediatric antibiotic trials, and several others, prompt the need for constant surveillance and immediate reaction.

This Special Issue aims to provide an open platform dedicated in presenting existing knowledge in the field of Pediatric Respiratory Infections (both community- and healthcare-associated infections), along with recording current trends in this field and shedding light to future prospects. Researchers from various scientific communities are welcome to present their latest research and discuss common themes and challenges.

Dr. Elias Iosifidis
Dr. Asterios Kampouras
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric respiratory tract infections;
  • epidemiology;
  • treatment;
  • surveillance;
  • antibiotic resistance;
  • host response

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

9 pages, 235 KiB  
Review
Pulmonary Infectious Complications in Children with Hematologic Malignancies and Chemotherapy-Induced Neutropenia
by Aikaterini Voulgaridou, Kleoniki I. Athanasiadou, Eftychia Athanasiadou, Emmanuel Roilides and Evgenia Papakonstantinou
Diseases 2020, 8(3), 32; https://doi.org/10.3390/diseases8030032 - 19 Aug 2020
Cited by 8 | Viewed by 2874
Abstract
Infections frequently complicate the treatment course in children with hematologic malignancies undergoing chemotherapy. Febrile neutropenia (FN) remains a major cause of hospital admissions in this population, and respiratory tract is often proven to be the site of infection even without respiratory signs and [...] Read more.
Infections frequently complicate the treatment course in children with hematologic malignancies undergoing chemotherapy. Febrile neutropenia (FN) remains a major cause of hospital admissions in this population, and respiratory tract is often proven to be the site of infection even without respiratory signs and symptoms. Clinical presentation may be subtle due to impaired inflammatory response. Common respiratory viruses and bacteria are widely identified in these patients, while fungi and, less commonly, bacteria are the causative agents in more severe cases. A detailed history, thorough clinical and basic laboratory examination along with a chest radiograph are the first steps in the evaluation of a child presenting signs of a pulmonary infection. After stratifying patient’s risk, prompt initiation of the appropriate empirical antimicrobial treatment is crucial and efficient for the majority of the patients. High-risk children should be treated with an intravenous antipseudomonal beta lactam agent, unless there is suspicion of multi-drug resistance when an antibiotic combination should be used. In unresponsive cases, more invasive procedures, including bronchoalveolar lavage (BAL), computed tomography (CT)-guided fine-needle aspiration or open lung biopsy (OLB), are recommended. Overall mortality rate can reach 20% with higher rates seen in cases unresponsive to initial therapy and those under mechanical ventilation. Full article
Back to TopTop